These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28915335)

  • 21. Molecular targets to treat muscular dystrophies.
    Kinter J; Sinnreich M
    Swiss Med Wkly; 2014 Feb; 144():w13916. PubMed ID: 24554202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular therapies in muscular dystrophies].
    Walter MC; Reilich P
    Fortschr Neurol Psychiatr; 2018 Sep; 86(9):535-542. PubMed ID: 30248686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collagen type VI myopathies.
    Bushby KM; Collins J; Hicks D
    Adv Exp Med Biol; 2014; 802():185-99. PubMed ID: 24443028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease?
    Taniguchi M; Kurahashi H; Noguchi S; Sese J; Okinaga T; Tsukahara T; Guicheney P; Ozono K; Nishino I; Morishita S; Toda T
    Biochem Biophys Res Commun; 2006 Apr; 342(2):489-502. PubMed ID: 16487936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Congenital Muscular Dystrophy and Congenital Myopathy.
    Butterfield RJ
    Continuum (Minneap Minn); 2019 Dec; 25(6):1640-1661. PubMed ID: 31794464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spectrum of muscular dystrophies associated with sarcolemmal-protein genetic defects.
    Nigro V; Piluso G
    Biochim Biophys Acta; 2015 Apr; 1852(4):585-93. PubMed ID: 25086336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human adipose-derived stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy.
    Alexeev V; Arita M; Donahue A; Bonaldo P; Chu ML; Igoucheva O
    Stem Cell Res Ther; 2014 Feb; 5(1):21. PubMed ID: 24522088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Congenital myopathies and congenital muscular dystrophies.
    Tubridy N; Fontaine B; Eymard B
    Curr Opin Neurol; 2001 Oct; 14(5):575-82. PubMed ID: 11562568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Childhood muscular dystrophies.
    Younger DS
    Handb Clin Neurol; 2023; 195():461-496. PubMed ID: 37562882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Congenital muscular dystrophies: toward molecular therapeutic interventions.
    Collins J; Bönnemann CG
    Curr Neurol Neurosci Rep; 2010 Mar; 10(2):83-91. PubMed ID: 20425232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distal myopathies.
    Barohn RJ; Amato AA
    Semin Neurol; 1999; 19(1):45-58. PubMed ID: 10711988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of fibrosis in muscular dystrophy.
    Smith LR; Barton ER
    Matrix Biol; 2018 Aug; 68-69():602-615. PubMed ID: 29408413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy for muscular dystrophy: lessons learned and path forward.
    Mendell JR; Rodino-Klapac L; Sahenk Z; Malik V; Kaspar BK; Walker CM; Clark KR
    Neurosci Lett; 2012 Oct; 527(2):90-9. PubMed ID: 22609847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of immune responses in gene/stem cell therapies for muscular dystrophies.
    Farini A; Sitzia C; Erratico S; Meregalli M; Torrente Y
    Biomed Res Int; 2014; 2014():818107. PubMed ID: 24959590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
    Rodrigues M; Yokota T
    Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic modifiers of muscular dystrophy: implications for therapy.
    Heydemann A; Doherty KR; McNally EM
    Biochim Biophys Acta; 2007 Feb; 1772(2):216-28. PubMed ID: 16916601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in muscular dystrophy research with special emphasis on gene therapy.
    Sugita H; Takeda S
    Proc Jpn Acad Ser B Phys Biol Sci; 2010; 86(7):748-56. PubMed ID: 20689232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory insight to congenital muscular dystrophies and congenital myopathies and its relation to clinical trial.
    Fauroux B; Amaddeo A; Quijano-Roy S; Barnerias C; Desguerre I; Khirani S
    Neuromuscul Disord; 2018 Sep; 28(9):731-740. PubMed ID: 30097248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Strategies of Muscular Dystrophy Therapeutics: An Overview.
    Lim KRQ; Yokota T
    Methods Mol Biol; 2023; 2587():3-30. PubMed ID: 36401021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental and therapeutic approaches to muscular dystrophies.
    Skuk D; Vilquin JT; Tremblay JP
    Curr Opin Neurol; 2002 Oct; 15(5):563-9. PubMed ID: 12352000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.